ERBB2 and breast cancer: Various guidelines support the use of trastuzumab-based chemotherapy as a standard option in tumors larger than 1 cm, and suggest its administration in T1b tumors because some studies have reported that HER2 overexpression was an independent, poor prognostic factor even for patients with pT1ab node-negative HER2+ breast cancer [6, 9].